ROCKVILLE, Md., June 20 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that it will sponsor a conference call today to discuss the U.S. Government’s agreement to purchase ABthrax(TM) (raxibacumab) for the Strategic National Stockpile.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )
The conference call will be hosted by senior management and will be held today, Tuesday, June 20, 2006, at 11:00 am Eastern Time.
Investors may listen to the call by dialing (913) 312-1298 or (800) 565- 5442, passcode 8274398, five to ten minutes before the start of the call. A replay of the conference call will be available several hours after the conference call by dialing (719) 457-0820 or (888) 203-1112, confirmation code 8274398, and will remain available for several days.
This conference call also will be webcast and may be accessed at http://www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.
The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.
HGS, Human Genome Sciences and ABthrax are trademarks of Human Genome Sciences, Inc.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company’s unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company’s ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company’s dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company’s filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
Photo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comHuman Genome Sciences, Inc.
CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, or Kate de Santis, Director, Investor Relations,+1-301-251-6003
Web site: http://www.hgsi.com/
Company News On-Call: http://www.prnewswire.com/comp/121115.html /
